3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
125
Recurrence
12
Neoplasms
8
Immunoglobulin Light-chain Amyloidosis
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Neoplasms, Plasma Cell
5
Smoldering Multiple Myeloma
4
Lymphoma
4
Leukemia, Myeloid, Acute
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Non-Hodgkin
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Plasmacytoma
2
Plasmablastic Lymphoma
2
Neoplasm, Residual
2
Myelodysplastic Syndromes
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Amyloidosis
2
Acute Kidney Injury
2
Triple Negative Breast Neoplasms
1
Proteostasis Deficiencies
1
Primary Myelofibrosis
1
Paraproteinemias
1
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Plasma Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
fludarabine
2
Cyclophosphamide
2
thymoglobulin
1
prednylidene
1
ofatumumab
1
deltacortene
1
daratumumab
1
carmustine, poliferprosan 20 drug combination
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Melphalan
1
Etoposide
1
Cytarabine
1
Carmustine
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Autoimmune Diseases of the Nervous System
×
daratumumab
×
1 year
×
Clear all
NCT06867991
2025-07-15
RADIA
The First People's Hospital of Changzhou
Phase 3
Recruiting
200 enrolled